Comparison of Immune Response Following Surgical Management of Renal Tumors
This study has been terminated.
Information provided by (Responsible Party):
Kenneth Ogan, MD, Emory University
First received: February 7, 2006
Last updated: September 23, 2013
Last verified: September 2013
Examine the effects of renal surgery on the immune system.
||Observational Model: Cohort
Time Perspective: Prospective
||Comparison of Immune Response Following Surgical Management of Renal Tumors
Biospecimen Retention: Samples Without DNA
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2006 (Final data collection date for primary outcome measure)
Prospective study examining the effects of different surgical procedures on immune function. This may have bearing on overall cancer specific recurrence and survival.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients undergoing open or laparoscopic surgeries for the treatment of kidney tumors.
- Kidney tumor patients scheduled for open or laparoscopic surgery
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00289146
|Atlanta, Georgia, United States, 30322 |
||Kenneth Ogan, MD
No publications provided
||Kenneth Ogan, MD, Associate Professor, Emory University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 7, 2006
||September 23, 2013
||United States: Food and Drug Administration
Keywords provided by Emory University:
kidney cancer, immunology
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 01, 2015
Carcinoma, Renal Cell
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial